8-K: Sensus Healthcare Reports Q1 2025 Financial Results: Revenue Declines, Company Forecasts Profitability for Remainder of Year

Sensus Healthcare announces Q1 2025 financial results with a revenue decrease but anticipates profitability for the rest of the year.

Summary

• Sensus Healthcare reported revenues of $8.3 million for the first quarter of 2025, compared to $10.7 million in the same period last year.
• The company experienced a net loss of $2.6 million, or $(0.16) per share, a stark contrast to the net income of $2.3 million, or $0.14 per diluted share, in Q1 2024.
• Adjusted EBITDA was negative $2.5 million, compared to a positive $3.0 million in the first quarter of 2024.
• Sensus Healthcare shipped 21 SRT systems during the quarter, including 15 to a large customer and one internationally.
• The company is forecasting profitability for the next three quarters and for the full year.
• They saw a 65% increase in treatment volume from FDAs over the preceding quarter.
• Cash and cash equivalents stood at $19.1 million as of March 31, 2025, down from $22.1 million at the end of 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the current quarter's results show a decline in revenue and a net loss, the company is projecting profitability for the remainder of the year and has seen growth in treatment volume from its FDA program. The increased investment in R&D and sales/marketing also suggests a forward-looking approach.

Positives

• Sensus Healthcare anticipates profitability for the remaining three quarters of 2025 and the full year.
• The company experienced a 65% increase in treatment volume from FDA-based SRT systems compared to the previous quarter.
• Sensus Healthcare expects to sign 3-5 additional multisite FDA customers this year.
• The company is well-positioned to meet anticipated future demand for SRT systems.

Negatives

• Revenues decreased to $8.3 million in Q1 2025 from $10.7 million in Q1 2024.
• The company reported a net loss of $2.6 million in Q1 2025, compared to a net income of $2.3 million in Q1 2024.
• Gross margin decreased to 53.0% in Q1 2025 from 62.6% in Q1 2024.
• Adjusted EBITDA was negative $2.5 million in Q1 2025, compared to $3.0 million in Q1 2024.

Risks

• Inflationary pressures could continue to impact sales.
• Changes in government or third-party payor reimbursement for clinical procedures could affect product purchases.
• The company faces customer concentration risks in the U.S. and China.
• The development of new competing products or technologies could render Sensus Healthcare's technology obsolete.
• Regulatory requirements and the ability to manage manufacturing processes and costs pose ongoing risks.
• Doing business in China and other foreign countries presents specific risks.
• The company's information technology systems and data security are subject to potential risks.
• The company's ability to protect its intellectual property and avoid infringing on the rights of others is crucial.

Future Outlook

Sensus Healthcare expects to be profitable in each of the next three quarters and for the full year. They anticipate revenue from FDAs to contribute meaningfully in the second half of the year and expect to sign 3-5 additional multisite FDA customers this year.

Management Comments

• Joe Sardano, Chairman and Chief Executive Officer, stated that the company invested in several important initiatives during the first quarter that are expected to benefit the business for the rest of the year and beyond.
• He also noted the strong response to their event at the AAD and the expansion of the Fair Deal Agreement (FDA) program.
• Management remains confident in their growth trajectory.

Industry Context

Sensus Healthcare operates in the medical device industry, specifically focusing on non-invasive treatments for skin cancer and keloids. The company's performance is influenced by factors such as technological advancements, regulatory approvals, reimbursement policies, and competition from other treatment modalities.

Comparison to Industry Standards

• Comparing Sensus Healthcare's performance to industry peers requires analyzing companies with similar product offerings and market focus, such as Accuray Incorporated (ARAY) in the radiation oncology space.
• Sensus Healthcare's gross margin of 53.0% in Q1 2025 can be benchmarked against the gross margins of medical device companies like Varian Medical Systems (VAR) (now part of Siemens Healthineers) to assess its competitiveness.
• The company's investment in research and development, which increased significantly in Q1 2025, can be compared to the R&D spending of companies like Elekta to gauge its commitment to innovation.
• The company's focus on FDA agreements can be compared to similar programs offered by competitors in the dermatology space.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the net loss, but reassured by the forecast of profitability for the rest of the year.
• Employees may be affected by the company's investments in sales and marketing and research and development.
• Customers may benefit from the company's focus on non-invasive treatments for skin cancer and keloids.
• Suppliers may be impacted by the company's manufacturing processes and costs.
• Creditors may be interested in the company's cash and cash equivalents and its ability to generate future profits.

Next Steps

• Management will host a conference call to discuss the financial results and provide a business update.
• The company will continue to participate in dermatology conferences to promote its Fair Deal Agreement (FDA) program.
• Sensus Healthcare will focus on finalizing the development of the TransDermal Infusion (TDI) product and enhancing products that incorporate IG-SRT technology.

Key Dates

Keywords

Sensus Healthcare, SRTS, financial results, first quarter, SRT systems, profitability, revenue, net loss, EBITDA, FDA